Literature DB >> 33175110

The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access.

Robert H Goldstein1,2, Rochelle P Walensky3,2.   

Abstract

Year:  2020        PMID： 33175110     DOI： 10.1001/jama.2020.21872

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.

Authors:  Mark Jarrett; Warren Licht; Kevin Bock; Zenobia Brown; Jamie Hirsch; Kevin Coppa; Rajdeep Brar; Stephen Bello; Ira Nash
Journal:  JMIRx Med       Date:  2021-09-27

2.  The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.

Authors:  Marie Kroemer; Laura Boullerot; Mélanie Ramseyer; Laurie Spehner; Christophe Barisien; Eleonore Gravelin; Adeline Renaudin; Fabrice Cognasse; Pierre Gallian; Olivier Hermine; Karine Lacombe; Pierre Tiberghien; Olivier Adotévi
Journal:  Front Public Health       Date:  2022-03-16

3.  Assessment of geographic access to monoclonal antibodies in the United States.

Authors:  Benjamin Rader; Christopher M Whaley; Wesley S Rogers; Professor John S Brownstein; Jonathan Cantor
Journal:  J Travel Med       Date:  2022-05-31       Impact factor: 39.194

4.  A Novel Approach to Equitable Distribution of Scarce Therapeutics: Institutional Experience Implementing a Reserve System for Allocation of COVID-19 Monoclonal Antibodies.

Authors:  Emily Rubin; Scott L Dryden-Peterson; Sarah P Hammond; Inga Lennes; Alyssa R Letourneau; Parag Pathak; Tayfun Sonmez; M Utku Ünver
Journal:  Chest       Date:  2021-08-06       Impact factor: 9.410
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.